Clinical trials: sponsored by Case Comprehensive Cancer Center
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation.
- Conditions
- HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- HPV (NCT05608369)
- Testing
- Cisplatin, Radiation therapy, Vorinostat
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Hematopoietic/Lymphoid Cancer
Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.
This clinical trial studies the use of a second infusion of donor hematopoietic cells that have had removal of T cells for the treatment of engraftment failure after a first hematopoietic stem cell transplant.
- Trial name
- NCT02158767
- Testing
- Allogenic T cell-depleted hematopoietic stem cell transplantation
- Where
- United States
- Sponsor
- Leland Metheny
Malignant Neoplasm of Prostate
Single-Port Versus Multi-Port Robotic Radical Prostatectomy
The purpose of this study is to compare two different techniques to perform the standard of care surgery to treat prostate cancer. This surgery is called robotic radical prostatectomy.
- Trial name
- NCT04696263
- Testing
- Da Vinci ® Xi system - MP Robotic Radical Prostatectomy, Da Vinci ® SP system - SP Robotic Radical Prostatectomy
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma, Cytokine Release Syndrome
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
The purpose of this study is to examine the safety, efficacy and feasibility of the use of one standard dose of siltuximab prior to teclistamab infusion.
- Conditions
- Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- NCT06352866
- Testing
- Siltuximab, Teclistamab(FDA-approved)
- Where
- United States
- Sponsor
- Jack Khouri, MD
Glioblastoma
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when…
- Trial name
- NCT03452579
- Testing
- Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- David Peereboom
Urothelial Carcinoma
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
The purpose of this study is to test the safety and effectiveness of immunotherapy (checkpoint inhibitor therapy) in advanced bladder cancer when given intermittently.
- Trial name
- NCT04322643
- Testing
- Pembrolizumab, Atezolizumab, Durvalumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01894061
- Testing
- Bevacizumab, NovoTTF-l00A, Quality of Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Diffuse Large B-Cell Lymphoma
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
This study is being done to evaluate if ME-401 can improve the treatment of patients with diffuse large b-celllymphoma (DLBCL). Many patients with DLBCL that are treated with the standard of care (R-CHOP) are cured.
- Trial name
- NCT04517435
- Testing
- ME-401, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Deepa Jagadeesh
Non Small Cell Lung Cancer
Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites
The purpose of this study is to determine if liquid biopsies will reduce time to begin treatment in participants with non-small cell lung cancer (NSCLC).
- Trial name
- NCT04474613
- Testing
- Liquid biopsy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
The purpose of this study is to treat participants with the combination of CPI-613 (the study drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and effective for participants with localized and…
- Trial name
- NCT03699319
- Testing
- CPI 613, Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- David Bajor, MD
Pulmonary Metastatic Osteosarcoma (pOS)
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
The purpose of this study is to evaluate the safety and tolerability of Natalizumab in children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS) and to assess clinical response associated with…
- Trial name
- NCT03811886
- Testing
- Natalizumab
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Metastatic or Unresectable Melanoma
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo®) and talazoparib (also known as Talzenna®) are when given as a combination treatment for unresectable or metastatic…
- Trial name
- NCT04187833
- Testing
- Nivolumab, Talazoparib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Graft Versus Host Disease
Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD
The purpose of this study is to see if two treatments (extracorporeal photopheresis and Mesenchymal Stromal Cell (MSC) infusion, can be given safely together, and if they improve the symptoms of a Graft versus Host Disease…
- Trial name
- NCT05333029
- Testing
- Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
- Where
- United States
- Sponsor
- Molly Gallogly
Colorectal Cancer, Colon Cancer
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
This study has two portions. The main goal of the Phase I portion of this research study is to see what doses of CB-839 and capecitabine can safely be given to patients without having too many side effects.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
- Trial name
- NCT02861300
- Testing
- CB-839, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- David Bajor, MD
Breast Cancer
Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer
This is a study of art-based and music-based therapy programs lasting three months (with additional follow-up 3 months after the end of the trial) in breast cancer patients currently receiving therapy as well as in cancer…
- Trial name
- NCT04493034
- Testing
- Art Therapy, Music Therapy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
The purpose of this study is to reduce the risk of cancer relapse by giving a donor lymphocyte infusion (DLI) to boost the immune system early after a stem cell transplant so that leukemia cells that escaped chemotherapy can be…
- Conditions
- Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT03939585
- Testing
- Cellular therapy product
- Where
- United States
- Sponsor
- Leland Metheny
Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor
Phase 2 Study of ONC201 in Neuroendocrine Tumors
The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in…
- Trial name
- NCT03034200
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter Anderson
Postoperative Pain Control, Opioid Consumption
Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery
The purpose of this study is to determine how a non-opioid pain control regimen, administered before and during surgery, will affect postoperative pain control and total opioid consumption in head and neck cancer participants…
- Trial name
- NCT04176419
- Testing
- Ketamine, Lidocaine, Acetaminophen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Reconstruction
Integrated Imaging System for In Vivo Visualization of Free Flap Perfusion Using Indocyanine Dye
The purpose of this study is to determine if the integrated imaging goggle (Smart Goggles) is as good as or better than current technology used to assess tissue perfusion (the extent of blood flow to the tissue) in certain types…
- Trial name
- NCT03625765
- Testing
- SmartGoggles
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells.
- Trial name
- NCT05312801
- Testing
- BAFF CAR-T
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Luminary Therapeutics